No Data
North China Pharmaceutical Withdraws Drug Registration for Antibiotic
North China Pharmaceutical (600812.SH): Withdraw the application for the registration of injectable polymyxin B sulfate pharmaceutical.
On December 16, Gelonghui reported that North China Pharmaceutical (600812.SH) announced that its wholly-owned subsidiary, Shenzhen Huayao Southern Pharmaceutical Co., Ltd. (referred to as "Southern Company"), submitted an application for the market approval of injectable colistin sulfate to the National Medical Products Administration in January 2024 and it has been accepted. Due to the need for further improvement of the pharmaceutical research submission materials for injectable colistin sulfate, Southern Company submitted a request to withdraw the registration of injectable colistin sulfate to the National Medical Products Administration. Recently, Southern Company received the "Notice of Termination of Drug Registration Application" for injectable colistin sulfate issued by the National Medical Products Administration.
North China Pharmaceutical (600812.SH) intends for some Pharmaceuticals to be selected for national centralized procurement.
North China Pharmaceutical (600812.SH) announced that on December 12, 2024, the company and its subsidiary Hua...
North China Pharmaceutical Company.Ltd's (SHSE:600812) Shares Lagging The Industry But So Is The Business
We Think That There Are Some Issues For North China Pharmaceutical Company.Ltd (SHSE:600812) Beyond Its Promising Earnings
North China Pharmaceutical (600812.SH): Subsidiary company received government subsidies
On October 30, GeLongHui announced that North China Pharmaceutical (600812.SH) disclosed that its subsidiary received a total of RMB 1.5584 million in government subsidies related to income from July 24, 2024 to the date of this announcement, accounting for 31.87% of the net income attributable to the shareholders of the listed company in 2023.
North China Pharmaceutical Company.Ltd (SHSE:600812) Not Doing Enough For Some Investors As Its Shares Slump 28%
No Data
